These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10581645)

  • 1. Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey.
    Bezard E; Brefel C; Tison F; Peyro-Saint-Paul H; Ladure P; Rascol O; Gross CE
    Prog Neuropsychopharmacol Biol Psychiatry; 1999 Oct; 23(7):1237-46. PubMed ID: 10581645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of (+/-)-idazoxan alone and in combination with L-DOPA methyl ester in MPTP-induced hemiparkinsonian monkeys.
    Domino EF; Ni L; Colpaert F; Marien M
    Recept Channels; 2003; 9(5):335-8. PubMed ID: 14527878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
    Henry B; Fox SH; Peggs D; Crossman AR; Brotchie JM
    Mov Disord; 1999 Sep; 14(5):744-53. PubMed ID: 10495035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys.
    Grondin R; Hadj Tahar A; Doan VD; Ladure P; Bédard PJ
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Feb; 361(2):181-6. PubMed ID: 10685874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.
    Ko WKD; Camus SM; Li Q; Yang J; McGuire S; Pioli EY; Bezard E
    Neuropharmacology; 2016 Nov; 110(Pt A):48-58. PubMed ID: 27424102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():27-38. PubMed ID: 25046277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.
    Fox SH; Henry B; Hill MP; Peggs D; Crossman AR; Brotchie JM
    Mov Disord; 2001 Jul; 16(4):642-50. PubMed ID: 11481687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?
    Srinivasan J; Schmidt WJ
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jun; 369(6):629-38. PubMed ID: 15118809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
    Hadj Tahar A; Ekesbo A; Grégoire L; Bangassoro E; Svensson KA; Tedroff J; Bédard PJ
    Eur J Pharmacol; 2001 Feb; 412(3):247-54. PubMed ID: 11166288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.
    Alam M; Danysz W; Schmidt WJ; Dekundy A
    Toxicol Appl Pharmacol; 2009 Oct; 240(2):198-207. PubMed ID: 19616571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats.
    Haapalinna A; Leino T; Heinonen E
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Nov; 368(5):342-51. PubMed ID: 14566451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys.
    Luquin MR; Obeso JA; Laguna J; Guillén J; Martínez-Lage JM
    Eur J Pharmacol; 1993 Apr; 235(2-3):297-300. PubMed ID: 7685291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G; Morissette M; Parent M; Di Paolo T
    Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of motor disability in MPTP-treated macaques using a telemetry system for estimating circadian motor activity.
    Barcia C; De Pablos V; Bautista-Hernández V; Sanchez-Bahillo A; Fernández-Barreiro A; Poza M; Herrero MT
    J Neurosci Methods; 2004 Mar; 134(1):59-64. PubMed ID: 15102503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists.
    Fredriksson A; Palomo T; Chase T; Archer T
    J Neural Transm (Vienna); 1999; 106(3-4):283-300. PubMed ID: 10392537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.
    Bezard E; Stutzmann JM; Imbert C; Boraud T; Boireau A; Gross CE
    Eur J Pharmacol; 1998 Sep; 356(2-3):101-4. PubMed ID: 9774238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.